Partner Services activation prerequisites and operations

The laboratory-only Control Plane presents four separate sections: Explore Services, My Connections, Program Configuration and Activity. Read failures are unavailable evidence, not zero activity or successful requests. Source contracts, disposable persistence, genuine hosted identity, partner acceptance and publication are independent evidence classes.

All five provider descriptors remain prospective and every operational verification fact is false. Core service authority is missing and the service gate is disabled. The source closeout completes design/test/documentation work only; it is not a live availability or certification announcement.

Do not activate a partner, apply SQL, send a packet, collect credentials, approve clinical use, invoice or publish the shared application as a consequence of reading this guide.

The Core operator must independently approve dependency scope, role grants, private reader/signing custody, retention, exact package hashes and rollback prerequisites. Security verifies bearer/tenant/environment isolation, no direct laboratory table or ledger access, immutable identities and append-only event history.

Current empty-table rollback refuses to erase evidence once records exist. An operator must preserve records and follow an independently approved forward remediation; source instructions are not permission to truncate or bypass history.

Name the laboratory and laboratory IT owner, current active Programs/versions/tests, exact collection methods/devices/specimens and service geography. Clinical reviewers own provider authorization, specimen stability, high-risk exclusions, critical-result governance and result-release responsibility.

Shamil/fractional technical lead coordinates integration and genuine acceptance. Laboratory IT owns account scope and interface evidence. Neither technical lead nor finance can sign clinical release or infer a vendor is certified from synthetic tests.

OpenLoop needs authenticated executed clauses, business sharing consent, manual submission procedure, account/partner decision and independent clinical authorization. Speedy Sticks needs explicit mobile geography; planned draw sites need separate location approval. Tasso needs per-orderable device/specimen review. DOT needs identified legal entity. Supera needs separate kit/inventory/outbound/return evidence.

Finance and legal verify business-only referral subject, qualified conversion, exclusions, currency/base/formula/window and independent legal/AKS/fee-splitting review before any manual economic claim. No rates or invoice actions are supplied by this product.

A future pilot needs signed lab/provider scopes, independently approved genuine Sandbox policy/identity and evidence from each existing operational system, followed by vendor/security/clinical signoff and deliberate Production authorization. Pausing or revoking metadata cannot erase past business evidence.

Source navigation/search/sitemap and generated developer text must resolve every guide. After a separately authorized release, GET clean documentation-host URLs and compare current availability text, changelog, sitemap and developer index. A 404 or stale page remains unverified propagation; source/build/CI success is not publication and grants no deployment permission.